Evaxin Biotech AS - Pipeline mit viel Potential - 500 Beiträge pro Seite
eröffnet am 16.02.21 20:33:15 von
neuester Beitrag 04.11.21 19:28:05 von
neuester Beitrag 04.11.21 19:28:05 von
Beiträge: 7
ID: 1.342.524
ID: 1.342.524
Aufrufe heute: 0
Gesamt: 593
Gesamt: 593
Aktive User: 0
ISIN: US29970R2040 · WKN: A400P5 · Symbol: EVAX
4,1700
USD
+0,24 %
+0,0100 USD
Letzter Kurs 02:00:00 NYSE
Neuigkeiten
24.01.24 · globenewswire  |
23.01.24 · globenewswire |
22.01.24 · globenewswire |
09.01.24 · globenewswire |
08.01.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5888 | +476,69 | |
| 7,0900 | +41,24 | |
| 1,8650 | +40,23 | |
| 1,7900 | +35,61 | |
| 3,9000 | +21,12 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9600 | -19,67 | |
| 25,81 | -22,12 | |
| 5,1700 | -23,97 | |
| 3,5000 | -26,24 | |
| 0,5103 | -40,66 |
Feedback
Einer der seltenen Werte aus dem Biotec-Sektor, die unmittelbar nach dem IPO zu Kursen unterhalb des IPO Preises zu haben sind und somit auch solchen Anlegern eine Einstiegschance geben, die beim IPO nicht zum Zug gekommen sind.
evaxion-biotech.com/pipeline/overview/default.aspx
Die Firma hat heute ihr neues Hauptquartier im DTU Science Park in Hoersholm bei Kopenhagen eröffnet :
finance.yahoo.com/news/...-office-laboratories-123000826.html
Insgesamt sind die Aussichten sehr gut, dass man in den kommenden Monaten einiges an News von Evaxion hören wird.
evaxion-biotech.com/pipeline/overview/default.aspx
Die Firma hat heute ihr neues Hauptquartier im DTU Science Park in Hoersholm bei Kopenhagen eröffnet :
finance.yahoo.com/news/...-office-laboratories-123000826.html
Insgesamt sind die Aussichten sehr gut, dass man in den kommenden Monaten einiges an News von Evaxion hören wird.
2. Versuch
Die Firma hat heute ihr neues Hauptquartier im DTU Science Park in Hoersholm bei Kopenhagen eröffnet :
https://finance.yahoo.com/news/evaxion-biotech-opens-office-…
Die Firma hat heute ihr neues Hauptquartier im DTU Science Park in Hoersholm bei Kopenhagen eröffnet :
https://finance.yahoo.com/news/evaxion-biotech-opens-office-…
Kurzportrait
Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections.
The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform.
It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery.
The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate.
Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.
Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections.
The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform.
It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery.
The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate.
Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.
Kurs liegt immer noch circa 25 % unterhalb des IPO Preises von Anfang Februar.
Jetzt kommen langsam erste Kaufempfehlungen rein:
Evaxion Biotech initiated with a Buy, $23 target at Ladenburg Ladenburg analyst Wangzhi Li initiated coverage of Evaxion Biotech with a Buy rating and $23 price target. Evaxion has built a "top-performing" neoAgs platform and pipeline that may potentially help address some of the current gaps for neoAgs vaccine, with "highly competitive" early clinical results shown, Li tells investors in a research note. The analyst sees the upcoming Phase 1/2 trial readouts in the first half of 2021 for Evaxion's two lead neoAgs vaccine programs as "potential significant near-term catalysts."
Evaxion Biotech initiated with an Outperform at Oppenheimer Oppenheimer analyst Kevin DeGeeter initiated coverage of Evaxion Biotech with an Outperform rating and $18 price target. DeGeeter expects that Evaxion, a February 2021 IPO, will report important data from EVX-01 and EVX-02 in 2Q21 including durability of response for low-dose EVX-01, T-cell data for high-dose EVX-01 and immunogenicity data for EVX-02, which may serve as an inflection point for shares and offer opportunity for further balance sheet expansion, the analyst tells investors in a research note.
Jetzt kommen langsam erste Kaufempfehlungen rein:
Evaxion Biotech initiated with a Buy, $23 target at Ladenburg Ladenburg analyst Wangzhi Li initiated coverage of Evaxion Biotech with a Buy rating and $23 price target. Evaxion has built a "top-performing" neoAgs platform and pipeline that may potentially help address some of the current gaps for neoAgs vaccine, with "highly competitive" early clinical results shown, Li tells investors in a research note. The analyst sees the upcoming Phase 1/2 trial readouts in the first half of 2021 for Evaxion's two lead neoAgs vaccine programs as "potential significant near-term catalysts."
Evaxion Biotech initiated with an Outperform at Oppenheimer Oppenheimer analyst Kevin DeGeeter initiated coverage of Evaxion Biotech with an Outperform rating and $18 price target. DeGeeter expects that Evaxion, a February 2021 IPO, will report important data from EVX-01 and EVX-02 in 2Q21 including durability of response for low-dose EVX-01, T-cell data for high-dose EVX-01 and immunogenicity data for EVX-02, which may serve as an inflection point for shares and offer opportunity for further balance sheet expansion, the analyst tells investors in a research note.
Ein attraktiver Rücksetzer.
Nächstes Jahr stehen die folgenden Termine an:
Nächstes Jahr stehen die folgenden Termine an:
Booooom was für eine Rakete
Der Kurs randaliert:
🎵
🎵
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,93 | |
| -1,07 | |
| +3,97 | |
| -2,71 | |
| -2,80 | |
| -2,66 | |
| -1,83 | |
| -1,60 | |
| -1,13 | |
| -0,76 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 176 | ||
| 156 | ||
| 73 | ||
| 64 | ||
| 62 | ||
| 62 | ||
| 28 | ||
| 26 | ||
| 26 | ||
| 25 |
23.01.24 · globenewswire · Evaxion Biotech |
09.01.24 · globenewswire · Evaxion Biotech |
22.12.23 · globenewswire · Evaxion Biotech |
20.12.23 · globenewswire · Evaxion Biotech |